| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Alport syndrome (AS) is a progressive hereditary kidney disease caused by mutation in collagen Type 4A3, A4 or A5, which are some of the components of glomerular basement membrane. Effective treatment for AS has not been established, and development of novel therapy is required. Here, we treated AS mice with MitoQ, which is an anti-oxidant that normalizes mitochondrial dysfunction by protecting against oxidative stress, and determined whether the mitochondrial dysfunction in AS is due to oxidative stress. Treatment of 6-week-old AS mice for 2 months ameliorates AS phenotypes such as renal fibrosis and kidney injury and inflammatory cytokines expression. Further investigations will reveal the causative molecules and signaling pathways that mediate mitochondrial dysfunction in Alport mice.
|
